Literature DB >> 22898789

Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance?

Isidro Machado1, José A López-Guerrero, Samuel Navarro, Marco Alberghini, Katia Scotlandi, Piero Picci, Antonio Llombart-Bosch.   

Abstract

Epithelial marker and adhesion molecule expression has been reported in Ewing's sarcoma family of tumors (ESFTs), although the prognostic significance has not been assessed systematically. We performed immunohistochemical analysis of epithelial cell adhesion molecule and epithelial mesenchymal transition markers on 415 genetically confirmed ESFTs. Survival analyses were performed in 217 patients. The atypical histological subtype expressed a high proportion of the epithelial markers compared with conventional and PNET variants. We observed that expression of desmoplakin (p < 0.001) and PI3K (p = 0.003) was higher in disseminated than in localized disease. Multivariate analysis showed that desmoplakin and pGSK3β constitute independent good prognostic factors for progression free survival (PFS), while ZO-1 and Snail represent independent good prognostic factors for overall survival (OS). In contrast, CK8/18 represents an independent poor prognostic factor for OS and the radiotherapy treatment group demonstrated an independent poor prognostic factor for PFS and OS. Although the expression of pan-cytokeratin has been previously highlighted in a significant proportion of ESFT, its expression did not reveal prognostic significance in the present series. Considering the results of prognostic analysis herein reported, we strongly recommend a prospective validation of at least the immunomarkers with prognostic significance (desmoplakin, ZO-1, CK8/18, pGSK3β, and Snail) in prospective series that include localized and disseminated tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22898789     DOI: 10.1007/s00428-012-1288-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  14 in total

1.  Keratin-positive Ewing's sarcoma: an ultrastructural study of 12 cases.

Authors:  Amitabh Srivastava; Andrew E Rosenberg; Martin Selig; Brian P Rubin; G Petur Nielsen
Journal:  Int J Surg Pathol       Date:  2005-01       Impact factor: 1.271

2.  Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors.

Authors:  José Antonio López-Guerrero; Isidro Machado; Katia Scotlandi; Rosa Noguera; Antonio Pellín; Samuel Navarro; Massimo Serra; Silvia Calabuig-Fariñas; Piero Picci; Antonio Llombart-Bosch
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

3.  Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support.

Authors:  Antonio Llombart-Bosch; Isidro Machado; Samuel Navarro; Franco Bertoni; Patrizia Bacchini; Marco Alberghini; Apollon Karzeladze; Nikita Savelov; Semyon Petrov; Isabel Alvarado-Cabrero; Doina Mihaila; Philippe Terrier; Jose Antonio Lopez-Guerrero; Piero Picci
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

4.  Epithelial marker expression does not rule out a diagnosis of Ewing's sarcoma family of tumours.

Authors:  Isidro Machado; Samuel Navarro; Jose A López-Guerrero; Marco Alberghini; Piero Picci; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2011-09-02       Impact factor: 4.064

5.  Snail is an independent prognostic predictor for progression and patient survival of gastric cancer.

Authors:  Hongyong He; Weidong Chen; Xuefei Wang; Cong Wang; Fenglin Liu; Zhenbin Shen; Jiejie Xu; Jianxin Gu; Yihong Sun
Journal:  Cancer Sci       Date:  2012-05-15       Impact factor: 6.716

6.  Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases.

Authors:  Andrew L Folpe; John R Goldblum; Brian P Rubin; Bahig M Shehata; Wendy Liu; Angelo P Dei Tos; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2005-08       Impact factor: 6.394

7.  Immunohistochemical study of correlation between histologic subtype and expression of epithelial-mesenchymal transition-related proteins in synovial sarcomas.

Authors:  Manish Mani Subramaniam; Samuel Navarro; Antonio Llombart-Bosch
Journal:  Arch Pathol Lab Med       Date:  2011-08       Impact factor: 5.534

8.  Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies.

Authors:  M Gu; C R Antonescu; G Guiter; A G Huvos; M Ladanyi; M F Zakowski
Journal:  Am J Surg Pathol       Date:  2000-03       Impact factor: 6.394

9.  Prognostic value of immunohistochemistry in the Ewing's sarcoma family of tumors.

Authors:  Rajko Kavalar; Ziva Pohar Marinsek; Berta Jereb; Branka Cagran; Rastko Golouh
Journal:  Med Sci Monit       Date:  2009-08

10.  Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus.

Authors:  T Makino; M Yamasaki; A Takeno; M Shirakawa; H Miyata; S Takiguchi; K Nakajima; Y Fujiwara; T Nishida; N Matsuura; M Mori; Y Doki
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more
  10 in total

1.  ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma.

Authors:  Elizabeth T Wiles; Russell Bell; Dafydd Thomas; Mary Beckerle; Stephen L Lessnick
Journal:  Genes Cancer       Date:  2013-11

2.  Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.

Authors:  Isidro Machado; José Antonio López Guerrero; Samuel Navarro; Empar Mayordomo; Katia Scotlandi; Piero Picci; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2013-05-17       Impact factor: 4.064

3.  MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.

Authors:  J Li; T You; J Jing
Journal:  Cell Prolif       Date:  2014-02-12       Impact factor: 6.831

4.  Down-regulated E-cadherin expression is associated with poor five-year overall survival in bone and soft tissue sarcoma: results of a meta-analysis.

Authors:  Ning Wang; Yong-Lai He; Li-Juan Pang; Hong Zou; Chun-Xia Liu; Jin Zhao; Jian-Ming Hu; Wen-Jie Zhang; Yan Qi; Feng Li
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

5.  Transforming growth factor-β1 signaling promotes epithelial-mesenchymal transition-like phenomena, cell motility, and cell invasion in synovial sarcoma cells.

Authors:  Yan Qi; Ning Wang; Yonglai He; Jun Zhang; Hong Zou; Wenjie Zhang; Wenyi Gu; Yalan Huang; Xiaojuan Lian; Jianming Hu; Jin Zhao; Xiaobin Cui; Lijuan Pang; Feng Li
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

6.  EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.

Authors:  Rikuka Shimizu; Miwa Tanaka; Shuichi Tsutsumi; Hiroyuki Aburatani; Yukari Yamazaki; Mizuki Homme; Yoshimasa Kitagawa; Takuro Nakamura
Journal:  Cancer Sci       Date:  2018-07-18       Impact factor: 6.716

7.  miR-185 suppresses progression of Ewing's sarcoma via inhibiting the PI3K/AKT and Wnt/β-catenin pathways.

Authors:  Shuai Zhang; Dong Li; Guang-Jun Jiao; Hong-Liang Wang; Ting-Bin Yan
Journal:  Onco Targets Ther       Date:  2018-11-09       Impact factor: 4.147

Review 8.  Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma.

Authors:  Sarah E Bosma; Pieter Baa van Driel; Pancras Cw Hogendoorn; Pd Sander Dijkstra; Cornelis Fm Sier
Journal:  J Surg Oncol       Date:  2018-09-13       Impact factor: 3.454

Review 9.  Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice.

Authors:  Chiara Agnoletto; Chiara Caruso; Cecilia Garofalo
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639

10.  Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.

Authors:  Neerav Shukla; Joshua Schiffman; Damon Reed; Ian J Davis; Richard B Womer; Stephen L Lessnick; Elizabeth R Lawlor
Journal:  Front Oncol       Date:  2013-06-06       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.